The global cancer diagnostics market in terms of revenue was estimated to be worth $17.2 billion in 2021 and is poised to reach $26.6 billion by 2026, growing at a CAGR of 11.5% from 2021 to 2026.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186559121
Key Market Players:
The major players in the cancer diagnostics market are Danaher Corporation (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US.), F. Hoffman-La Roche AG (Switzerland), QIAGEN N.V. (Netherlands), Fujifilm Corporation (Japan), Aglient Technologies (US) and Thermo Fisher Scientific Inc. (US) etc.
By product, the cancer diagnostics market is segmented into consumables and instruments. In 2020, the instruments segment accounted for the larger share of the cancer diagnostics market. The large share of this segment can be attributed increasing incidence of cancer.
Based on the technology, the cancer diagnostics market is segmented into IVD testing, Imaging Based and biopsy techniques. In 2020, the IVD testing segment accounted for the largest share of the cancer diagnostics market. The large share of this segment can be attributed to incidences of cancer and technological advancement.
Based on application, the cancer diagnostics market is segmented into breast cancer, lung cancer, colorectal cancer, melanoma, and other cancer. The breast cancer segment accounted for the largest market share in 2020. The increasing incidence of breast cancer are the major driving factors for this market.
By end user, the cancer diagnostics market is segmented into a hospitals and diagnostic laboratories. The hospitals segment accounted for the largest market share in 2020. The increasing number of patients visiting hospitals, rising number of in-house diagnostic procedures performed in hospitals, are the major driving factors for this market.
Request Free Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=186559121
